SEC Form 4 · accession 0001127602-17-031249
PDS Biotechnology Corp · PDSB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian A Leuthner
Officer — President and CEO · Director
Period of report
Nov 1, 2017
Accepted (ET)
Nov 3, 2017 · 5:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001472091
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 1, 2017 | S | 2,500 | $10.92 | D | 102,736 | D | |
| Common StockF3 | Nov 2, 2017 | S | 2,500 | $10.94 | D | 100,236 | D | |
| Common StockF4 | Nov 3, 2017 | S | 2,500 | $10.86 | D | 97,736 | D | |
| Common StockF5 | holding | — | — | — | 162,000 | I | By Spouse | |
| Common StockF6 | holding | — | — | — | 223,622 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.40 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.70 to $11.08 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.62 to $11.02 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- F6The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.